These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

102 related articles for article (PubMed ID: 15290453)

  • 1. In vitro antimicrobial activity of T-91825, a novel anti-MRSA cephalosporin, and in vivo anti-MRSA activity of its prodrug, TAK-599.
    Iizawa Y; Nagai J; Ishikawa T; Hashiguchi S; Nakao M; Miyake A; Okonogi K
    J Infect Chemother; 2004 Jun; 10(3):146-56. PubMed ID: 15290453
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Pharmacodynamics of a new cephalosporin, PPI-0903 (TAK-599), active against methicillin-resistant Staphylococcus aureus in murine thigh and lung infection models: identification of an in vivo pharmacokinetic-pharmacodynamic target.
    Andes D; Craig WA
    Antimicrob Agents Chemother; 2006 Apr; 50(4):1376-83. PubMed ID: 16569855
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Activity of ceftobiprole against methicillin-resistant Staphylococcus aureus strains with reduced susceptibility to daptomycin, linezolid or vancomycin, and strains with defined SCCmec types.
    Farrell DJ; Flamm RK; Sader HS; Jones RN
    Int J Antimicrob Agents; 2014 Apr; 43(4):323-7. PubMed ID: 24411474
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Efficacy of tedizolid against methicillin-resistant Staphylococcus aureus and Peptostreptococcus anaerobius in thigh mixed-infection mouse model.
    Yamagishi Y; Mikamo H; Kato H; Nishiyama N; Asai N; Koizumi Y; Sakanashi D; Suematsu H; Matsuura K; Hagihara M
    J Infect Chemother; 2017 Jun; 23(6):368-373. PubMed ID: 28343752
    [TBL] [Abstract][Full Text] [Related]  

  • 5. In vivo antibacterial activity of S-3578, a new broad-spectrum cephalosporin: methicillin-resistant Staphylococcus aureus and Pseudomonas aeruginosa experimental infection models.
    Tsuji M; Takema M; Miwa H; Shimada J; Kuwahara S
    Antimicrob Agents Chemother; 2003 Aug; 47(8):2507-12. PubMed ID: 12878512
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The importance of tissue penetration in achieving successful antimicrobial treatment of nosocomial pneumonia and complicated skin and soft-tissue infections caused by methicillin-resistant Staphylococcus aureus: vancomycin and linezolid.
    Stein GE; Wells EM
    Curr Med Res Opin; 2010 Mar; 26(3):571-88. PubMed ID: 20055750
    [TBL] [Abstract][Full Text] [Related]  

  • 7. MRSA--the tip of the iceberg.
    Appelbaum PC
    Clin Microbiol Infect; 2006 Apr; 12 Suppl 2():3-10. PubMed ID: 16524422
    [TBL] [Abstract][Full Text] [Related]  

  • 8. In-vitro profile of a new beta-lactam, ceftobiprole, with activity against methicillin-resistant Staphylococcus aureus.
    Jones ME
    Clin Microbiol Infect; 2007 Jun; 13 Suppl 2():17-24. PubMed ID: 17488372
    [TBL] [Abstract][Full Text] [Related]  

  • 9. TOC-39, a novel parenteral broad-spectrum cephalosporin with excellent activity against methicillin-resistant Staphylococcus aureus.
    Hanaki H; Akagi H; Masaru Y; Otani T; Hyodo A; Hiramatsu K
    Antimicrob Agents Chemother; 1995 May; 39(5):1120-6. PubMed ID: 7625799
    [TBL] [Abstract][Full Text] [Related]  

  • 10. CP6679, a new injectable cephalosporin with broad spectrum and potent activities against methicillin-resistant Staphylococcus aureus and Pseudomonas aeruginosa.
    Ida T; Tsushima M; Ishii T; Atsumi K; Tamura A
    J Infect Chemother; 2002 Jun; 8(2):138-44. PubMed ID: 12111566
    [TBL] [Abstract][Full Text] [Related]  

  • 11.
    Gaikwad V; Gohel T; Panickar S; Chincholkar V; Mangalkar S
    Indian J Pathol Microbiol; 2016; 59(4):496-498. PubMed ID: 27721280
    [TBL] [Abstract][Full Text] [Related]  

  • 12. In vitro and in vivo activities of echinomycin against clinical isolates of Staphylococcus aureus.
    Park YS; Shin WS; Kim SK
    J Antimicrob Chemother; 2008 Jan; 61(1):163-8. PubMed ID: 17967852
    [TBL] [Abstract][Full Text] [Related]  

  • 13. In vitro and in vivo properties of Ro 63-9141, a novel broad-spectrum cephalosporin with activity against methicillin-resistant staphylococci.
    Hebeisen P; Heinze-Krauss I; Angehrn P; Hohl P; Page MG; Then RL
    Antimicrob Agents Chemother; 2001 Mar; 45(3):825-36. PubMed ID: 11181368
    [TBL] [Abstract][Full Text] [Related]  

  • 14. In vitro activities of a novel cephalosporin, CB-181963 (CAB-175), against methicillin-susceptible or -resistant Staphylococcus aureus and glycopeptide-intermediate susceptible staphylococci.
    Huang V; Brown WJ; Rybak MJ
    Antimicrob Agents Chemother; 2004 Jul; 48(7):2719-23. PubMed ID: 15215134
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Pharmacodynamic activity of ceftobiprole compared with vancomycin versus methicillin-resistant Staphylococcus aureus (MRSA), vancomycin-intermediate Staphylococcus aureus (VISA) and vancomycin-resistant Staphylococcus aureus (VRSA) using an in vitro model.
    Zhanel GG; Voth D; Nichol K; Karlowsky JA; Noreddin AM; Hoban DJ
    J Antimicrob Chemother; 2009 Aug; 64(2):364-9. PubMed ID: 19454524
    [TBL] [Abstract][Full Text] [Related]  

  • 16. TAK-599, a novel N-phosphono type prodrug of anti-MRSA cephalosporin T-91825: synthesis, physicochemical and pharmacological properties.
    Ishikawa T; Matsunaga N; Tawada H; Kuroda N; Nakayama Y; Ishibashi Y; Tomimoto M; Ikeda Y; Tagawa Y; Iizawa Y; Okonogi K; Hashiguchi S; Miyake A
    Bioorg Med Chem; 2003 May; 11(11):2427-37. PubMed ID: 12735989
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Ceftaroline: a novel cephalosporin with activity against methicillin-resistant Staphylococcus aureus.
    Saravolatz LD; Stein GE; Johnson LB
    Clin Infect Dis; 2011 May; 52(9):1156-63. PubMed ID: 21467022
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Comparative in vitro activity of linezolid and five other antimicrobials against nosocomial isolates of methicillin-resistant Staphylococcus aureus, methicillin-resistant Staphylococcus epidermidis and vancomycin-resistant Enterococcus faecium.
    Metallidis S; Chatzidimitriou M; Nikolaidis P; Tsona A; Bisiklis A; Kollaras P; Tsiakiri E; Koumentaki E; Alexiou-Daniel S
    J Chemother; 2003 Oct; 15(5):442-8. PubMed ID: 14603881
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Increased activity of linezolid in combination with rifampicin in a murine pneumonia model due to MRSA.
    Zhou YF; Xiong YQ; Tao MT; Li L; Bu MX; Sun J; Liao XP; Liu YH
    J Antimicrob Chemother; 2018 Jul; 73(7):1899-1907. PubMed ID: 29897466
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Time-kill kinetics of oritavancin and comparator agents against Staphylococcus aureus, Enterococcus faecalis and Enterococcus faecium.
    McKay GA; Beaulieu S; Arhin FF; Belley A; Sarmiento I; Parr T; Moeck G
    J Antimicrob Chemother; 2009 Jun; 63(6):1191-9. PubMed ID: 19369269
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.